EDP Sciences logo
Authentification abonné
rechercher
Menu
Accueil Tous les numéros Volume 212 / Numéro 3-4 (2018) Biologie Aujourd'hui, 212 3-4 (2018) 81-84 Références
Accès gratuit
Numéro
Biologie Aujourd'hui
Volume 212, Numéro 3-4, 2018
Page(s) 81 - 84
DOI https://doi.org/10.1051/jbio/2018028
Publié en ligne 11 avril 2019
  • Balar, A.V., Castellano, D., O’Donnell, P.H., Grivas, P., Vuky, J., Powles, T., Plimack, E.R., Hahn, N.M., de Wit, R., Pang, L., Savage M.J., Perini, R.F., Keefe, S.M., Bajorin, D., Bellmunt, J. (2017a). First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): A multicentre, single-arm, phase 2 study. Lancet Oncol, 18, 1483-1492. [CrossRef] [Google Scholar]
  • Balar, A.V., Galsky, M.D., Rosenberg, J.E., Powles, T., Petrylak, D.P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., Perez-Gracia, J.L., Dawson, N.A., van der Heijden, M.S., Dreicer, R., Srinivas, S., Retz, M.M., Joseph, R.W., Drakaki, A., Vaishampayan, U.N., Sridhar, S.S., Quinn, D.I., Durán, I., Shaffer, D.R., Eigl, B.J., Grivas, PD., Yu, EY., Li, S., Kadel, E.E. 3rd, Boyd, Z., Bourgon, R., Hegde, P.S., Mariathasan, S., Thåström, A., Abidoye, O.O., Fine, G.D., Bajorin, D.F. (2017b). Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: A single-arm, multicentre, phase 2 trial. Lancet, 389, 67-76. [Google Scholar]
  • Bellmunt, J., de Wit, R., Vaughn, D.J., Fradet, Y., Lee, J.L., Fong, L., Vogelzang, N.J., Climent, M.A., Petrylak, D.P., Choueiri, T.K., Necchi, A., Gerritsen, W., Gurney, H., Quinn, D.I., Culine, S., Sternberg, C.N., Mai, Y., Poehlein, C.H., Perini, R.F., Bajorin, D.F. (2017). Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med, 376, 1015-1026. [CrossRef] [PubMed] [Google Scholar]
  • Calmette, A. (1931). Preventive vaccination against tuberculosis with BCG. Proc R Soc Med, 24, 1481-1490. [PubMed] [Google Scholar]
  • Carosella, E.D., Ploussard, G., LeMaoult, J., Desgrandchamps, F. (2015). A systematic review of immunotherapy in urologic cancer: Evolving roles for targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Eur Urol, 68, 267-279. [CrossRef] [PubMed] [Google Scholar]
  • Fellows, G.J., Parmar, M.K., Grigor, K.M., Hall, R.R., Heal, M.R., Wallace, D.M. (1994). Marker tumour response to Evans and Pasteur bacille Calmette-Guérin in multiple recurrent pTa/pT1 bladder tumours: Report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). Br J Urol, 73, 639-644. [CrossRef] [PubMed] [Google Scholar]
  • Herr, H.W., Morales, A. (2008). History of bacillus Calmette-Guérin and bladder cancer: An immunotherapy success story. J Urol, 179, 53-56. [CrossRef] [PubMed] [Google Scholar]
  • Inamoto, T., Ubai, T., Nishida, T., Fujisue, Y., Katsuoka, Y., Azuma, H. (2013). Comparable effect with minimal morbidity of low-dose Tokyo 172 strain compared with regular dose Connaught strain as an intravesical bacillus Calmette-Guérin prophylaxis in nonmuscle invasive bladder cancer: Results of a randomized prospective comparison. Urol Ann, 5, 7-12. [CrossRef] [PubMed] [Google Scholar]
  • Kavoussi, L.R., Brown, E.J., Ritchey, J.K., Ratliff, T.L. (1990). Fibronectin-mediated Calmette-Guérin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. J Clin Invest, 85, 62-67. [CrossRef] [PubMed] [Google Scholar]
  • Lamm, D.L. (1992). Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am, 19, 573-580. [PubMed] [Google Scholar]
  • Lamm, D.L., Blumenstein, B.A., Crissman, J.D., Montie, J.E., Gottesman, J.E., Lowe, B.A., Sarosdy, M.F., Bohl, R.D., Grossman, H.B., Beck, T.M., Leimert, J.T., Crawford, E.D. (2000). Maintenance bacillus Calmette-Guérin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group Study. J Urol, 163, 1124-1129. [CrossRef] [PubMed] [Google Scholar]
  • Malmström, P.U., Sylvester, R.J., Crawford, D.E., Friedrich, M., Krege, S., Rintala, E., Solsona, E., Di Stasi, S.M., Witjes, J.A. (2009). An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol, 56, 247-256. [CrossRef] [PubMed] [Google Scholar]
  • Morales, A., Eidinger, D., Bruce, A.W. (1976). Intracavitary Bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol, 116, 180-183. [CrossRef] [PubMed] [Google Scholar]
  • Neuzillet, Y., Rouprêt, M., Larre, S., Irani, J., Davin, J.L., Moreau, J.L., Pfister, C. (2013). [Diagnosis and management of severe adverse events occurring during BCG therapy for non-muscle invasive bladder cancer (NMIBC)]. Presse Med, 42, 1100-1108. [CrossRef] [PubMed] [Google Scholar]
  • Oddens, J., Brausi, M., Sylvester, R., Bono, A., van de Beek, C., van Andel, G., Gontero, P., Hoeltl, W., Turkeri, L., Marreaud, S., Collette, S., Oosterlinck, W. (2013). Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: One-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol, 63, 462-472. [CrossRef] [Google Scholar]
  • Plimack, E.R., Bellmunt, J., Gupta, S., Berger, R., Chow, L.Q., Juco, J., Lunceford, J., Saraf, S., Perini, R.F., O’Donnell, P.H. (2017). Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): A non-randomised, open-label, phase 1b study. Lancet Oncol, 18, 212-220. [CrossRef] [PubMed] [Google Scholar]
  • Rentsch, C.A., Birkhauser, F.D., Biot, C., Gsponer, J.R., Bisiaux, A., Wetterauer, C., Lagranderie, M., Marchal, G., Orgeur, M., Bouchier, C., Bachmann A., Ingersoll M.A., Brosch, R., Albert, M.L., Thalmann, G.N. (2014). Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. Eur Urol, 66, 677-688. [CrossRef] [PubMed] [Google Scholar]
  • Rodriguez-Alvarez, M., Mendoza-Hernandez, G., Encarnacion, S., Calva, J.J., Lopez-Vidal, Y. (2009). Phenotypic differences between BCG vaccines at the proteome level. Tuberculosis (Edinb), 89, 126-135. [CrossRef] [PubMed] [Google Scholar]
  • Rouprêt, M., Neuzillet, Y., Larré, S., Pignot, G., Coloby, P., Rébillard, X., Mongiat-Artus, P., Chartier-Kastler, E., Soulié, M., Pfister, C. (2012). Comité de Cancérologie de l’Association Française d’Urologie. [Guidelines for good practice of intravesical instillations of BCG and mitomycin C from the French national cancer committee (CC-AFU) for non-muscle invasive bladder cancer]. Prog Urol, 22, 920-931. [CrossRef] [PubMed] [Google Scholar]
  • Rouprêt, M., Neuzillet, Y., Pignot, G., Compérat, E., Audenet, F., Houédé, N., Larré, S., Masson-Lecomte, A., Colin, P., Brunelle, S., Xylinas, E., Roumiguié, M., Méjean, A. (2018). [French ccAFU guidelines-Update 2018-2020: Bladder cancer]. Prog Urol, 28, S46-S78. [CrossRef] [PubMed] [Google Scholar]
  • Sengiku, A., Ito, M., Miyazaki, Y., Sawazaki, H., Takahashi, T., Ogura, K. (2013). A prospective comparative study of intravesical bacillus Calmette-Guérin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer. J Urol, 190, 50-54. [CrossRef] [PubMed] [Google Scholar]
  • Sylvester, R.J., van der Meijden, M.A., Lamm, D.L. (2002). Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials. J Urol, 168, 1964-1970. [CrossRef] [Google Scholar]
  • Sylvester, R.J., van der Meijden, A.P., Oosterlinck, W., Witjes, J.A., Bouffioux, C., Denis, L., Newling, D.W., Kurth, K. (2006). Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur Urol, 49, 466-465; 475-467. [CrossRef] [Google Scholar]
  • Uhry, Z., Remontet, L., Colonna, M., Belot, A., Grosclaude, P., Mitton, N., Delacour-Billon, S., Gentil, J., Boussac-Zarebska, M., Bossard, N., Danzon, A., Altana, M., Frete, F., Weill, A., Rogel, A. (2013). Cancer incidence estimation at a district level without a national registry: A validation study for 24 cancer sites using French health insurance and registry data. Cancer Epidemiol, 37, 99-114. [CrossRef] [Google Scholar]
  • Vegt, P.D., Witjes, J.A., Witjes, W.P., Doesburg, W.H., Debruyne, F.M., van der Meijden, A.P. (1995). A randomized study of intravesical mitomycin C, bacillus Calmette-Guérin Tice and bacillus Calmette-Guérin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder. J Urol, 153, 929-933. [CrossRef] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.